Latest news
FMR LLC reports 9.2% Eikon Therapeutics (EIKN) ownership on amended 13G - Stock TitanStock Titan · Thu, 06 Aug 2026 14:21:02 GMTEikon Therapeutics (EIKN US): Synthetic Expert Call Transcript (04 Aug 2026) - SmartkarmaSmartkarma · Tue, 04 Aug 2026 14:03:18 GMTCertain Warrants of Eikon Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-AUG-2026. - marketscreener.commarketscreener.com · Tue, 04 Aug 2026 00:21:41 GMTTwo Eikon Therapeutics, Inc. (Nasdaq: EIKN) directors step down - Stock TitanStock Titan · Mon, 03 Aug 2026 20:40:42 GMTEikon Therapeutics (EIKN): Six Months Later: Priced for Perfection, Punished by Reality - SmartkarmaSmartkarma · Mon, 03 Aug 2026 07:00:00 GMTBaker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks M - BenzingaBenzinga · Mon, 27 Jul 2026 14:35:13 GMTEikon Therapeutics Announces First Patient Dosed in - GlobeNewswireGlobeNewswire · Mon, 27 Jul 2026 11:30:00 GMTEikon Therapeutics Doses First Patient in Phase 2/3 TeLuRide-008 Trial of EIK1001 for First-Line Stage 4 NSCLC - Quiver QuantitativeQuiver Quantitative · Mon, 27 Jul 2026 07:00:00 GMT